Datopotamab Deruxtecan Significantly Extended Progression-Free Survival Versus Chemotherapy in Patients with HR Positive, HER2 Low or Negative Breast Cancer in TROPION-Breast01 Phase 3 Trial
PFS 6.9 vs 4.9 months(hazard ratio [HR]=0.63; 95% confidence interval [CI]: 0.52-0.76; p<0.0001)
ORR 36.4 vs 22.9%
OS HR=0.84; 95% CI: 0.62-1.14でfavored datopotamab
deruxtecan だけどresults did not reach statistical
significance at the time of this data cut-off
ぴえん
英字サイトにはIR出ていますね。
Datopotamab Deruxtecan Significantly Extended Progression-Free Survival Versus Chemotherapy in Patients with HR Positive, HER2 Low or Negative Breast Cancer in TROPION-Breast01 Phase 3 Trial
PFS 6.9 vs 4.9 months(hazard ratio [HR]=0.63; 95% confidence interval [CI]: 0.52-0.76; p<0.0001)
ORR 36.4 vs 22.9%
OS HR=0.84; 95% CI: 0.62-1.14でfavored datopotamab
deruxtecan だけどresults did not reach statistical
significance at the time of this data cut-off